The Federal Antimonopoly Service (FAS) acknowledged the violation of Arbidol medicine advertising, which spoke of its effectiveness against a new type of coronavirus.
The manufacturer of the drug OTCPharm distributed a commercial on the radio stations in 2020 stating that Arbidol is effective against a new type of coronavirus (COVID-2019).
The drug’s instructions say that the drug is an antiviral drug that suppresses in vitro influenza A and B viruses, pathogens of acute respiratory infections and coronavirus associated with severe acute respiratory syndrome (SARS).
At the same time, the Ministry of Health did not receive a request to expand the indications for the use of Arbidol.
The FAS acknowledged this as a violation and issued an order to terminate the violation. The penalty for such a violation of the law on advertising is from 200 to 500 thousand rubles.